Brief: Alk Says Co Licenses Rights To Neffy
09/11/2024 22:32
Nov 9 (Reuters) - ALK-Abello A/S ALKb.CO :
* REG-ALK LICENSES RIGHTS TO NEFFY®, THE FIRST APPROVED
ADRENALINE
NASAL SPRAY FOR EMERGENCY TREATMENT OF ALLERGIC REACTIONS
(ANAPHYLAXIS)
* ALK-ABELLO A/S - ALK TO PAY USD 145 MILLION IN UPFRONT AND
ADDITIONAL FUTURE MILESTONES AND SALES ROYALTIES
Source text: ID:nGNE86tMlH
Further company coverage: ALKb.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle